Home Newsfeeds Onconova Therapeutics Announces Rigosertib Data Presented At EADV As Late Breaker

Onconova Therapeutics Announces Rigosertib Data Presented At EADV As Late Breaker

Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a

byBenzinga Newsdesk

October 12, 2023

1 minute read

Onconova Therapeutics, Inc. (NASDAQ:Scientific Presentations section of the Onconova website following the Presentation.

SVB Leerink Upgrades Satsuma Pharmaceuticals to Outperform, Raises Price Target to $15

By Benzinga Newsdesk

October 10, 6:58 AM

SVB Leerink analyst Marc Goodman upgrades Satsuma Pharmaceuticals (NASDAQ:STSA) from Market Perform to Outperform and raises the price target from $5 to $15.

STSA

Morphic Therapeutic’s Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars

By Vandana Singh

April 25, 9:54 AM

Morphic Therapeutic (NASDAQ:MORF) reported topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral…

MORF

Summit Midstream Partners Q3 EPS $(1.28) Down From $(0.17) YoY, Sales $88.68M Down From $102.05M YoY

By Benzinga Newsdesk

November 3, 5:40 PM

Summit Midstream Partners (NYSE:SMLP) reported quarterly losses of $(1.28) per share. This is a 652.94 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $88.68

SMLP

Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members

By Vandana Singh

April 1, 8:45 AM

Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kathy Turner. Ancora's significant stake in Elanco, approximately $250 million, has driven discussions on board restructuring and CEO succession planning.

ELAN

Onconova Therapeutics Announces Rigosertib Data Presented At EADV As Late Breaker

Related Posts

SVB Leerink Upgrades Satsuma Pharmaceuticals to Outperform, Raises Price Target to $15

Morphic Therapeutic’s Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars

Summit Midstream Partners Q3 EPS $(1.28) Down From $(0.17) YoY, Sales $88.68M Down From $102.05M YoY

Investor Activism: Elanco Animal Health Settles with Ancora, Adds New Board Members